MOMETASONE FUROATE | N020762 | ORGANON LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. 1 patentANDA 205149mometasone furoate | D. Del. | 2014-07-03 | Terminated 2016-11-16 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Aurobindo Pharma USA Inc FDA-2022-P-0077 · 6 docket documents Aurobindo Pharma USA Inc filed this citizen petition on January 14, 2022, requesting that the FDA determine whether NASONEX (mometasone furoate monohydrate) Nasal Spray 0.05 mg/spray under NDA 020762 held by Organon LLC was voluntarily withdrawn from sale for safety or effectiveness reasons, citing | 505(q) | 2022-01-18 | Granted | Aurobindo Pharma USA Inc |
Merck Sharpe & Dohme Corporation - Citizen Petition FDA-2012-P-0749 · 3 docket documents Merck Sharp & Dohme Corporation filed this citizen petition concerning mometasone furoate aqueous nasal spray, requesting approval of the formulation and manufacturing method for this suspension product intended to treat seasonal and perennial allergic and non-allergic rhinitis, with the formulation | Other | 2012-07-31 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.